In conclusion, the results strongly suggest that A4276 is an NAMPT inhibitor that exhibits remarkable selectivity against NAPRT-deficient EMT-like cancer cell lines across various cancer types while effectively sparing NAPRT-positive cells, particularly, normal cells. The gene discussed is NAPRT; the disease is cancer.